Chemours 10-Q: $196M Q3 Profit Masks $107M Nine-Month Loss on $307M Tax Charge
CC sits 22% above its 52-week low of $10.44.
Summary
Chemours posted $196 million of Q3 net income ($1.29 per share) but a $107 million nine-month loss after a $307 million tax valuation allowance. PFAS settlement reserves and environmental liabilities rose sharply, while the New Jersey and North Carolina deals are now funded.
Key Events · Earnings and Guidance · CC
-
Q3 Profit Boosted by One-Time Items
Net income of $196 million, or $1.29 per diluted share, versus $46 million and $0.31 a year earlier. SG&A was a $25 million credit, including $150 million received under the PFAS Insurance MOU, and other income included a $50 million gain on the final Kuan Yin land parcel.
-
Full U.S. Tax Valuation Allowance Drives Nine-Month Loss
The nine-month provision for income taxes was $307 million, including a full valuation allowance against U.S. federal and state deferred tax assets with roughly $208 million tied to prior-year DTAs. That turned a $200 million pre-tax profit into a $107 million net loss.
-
PFAS Settlements Now Quantified and Funded
The New Jersey consent order became final in September 2026: $875 million of payments over 25 years, with Chemours' 50% share carried at $176 million net present value after a $100 million first payment. The North Carolina settlement totals $455 million over 15 years with $205 million reserved.
-
Environmental Reserves Jump on Consent Decree
Environmental remediation liabilities rose to $805 million from $618 million, including $136 million of charges from the 2026 EPA/WVDEP Consent Decree expanding off-site drinking water programs at Washington Works and Chambers Works.
Analysis · CC · Industrial Applications And Services
The quarter looked strong on the surface: net income of $196 million, or $1.29 per diluted share, versus $46 million a year earlier. But roughly $150 million of that came from a one-time PFAS insurance escrow payment booked as an SG&A credit, and $50 million from the final Kuan Yin land parcel sale. Strip those out and the operating picture softens: Thermal & Specialized Solutions EBITDA fell 30% to $136 million on a 9% volume decline as the 2025 refrigerant transition demand faded. The bigger story is the balance sheet. Nine-month results show a $107 million loss because Chemours took a full valuation allowance against its U.S. federal and state deferred tax assets, a $307 million provision that signals management no longer expects to reliably generate taxable U.S. profit. Against that, PFAS liabilities are now quantified and funded: the New Jersey consent order is final at $875 million over 25 years (Chemours' half carried at $176 million net present value), North Carolina settled at $455 million, and environmental reserves jumped to $805 million from $618 million. Liquidity is adequate — $698 million of cash and $953 million of revolver availability — but Moody's cut the rating to B1 in July, so refinancing costs matter.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CC was trading at $12.75 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $10.44 to $28.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.